Drugs / GB242
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04178850 | Oct 2017 → Dec 2020 | rheumatoid arthritis | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB242 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04178850 ↗ |
| Action | Inhibit | “Anti-TNF-alpha antibodies” NCT04178850 ↗ |
| Modality | Monoclonal antibody | “Recombinant Human-mouse Chimeric Anti-TNF-alpha Monoclonal Antibody for Injection” NCT04178850 ↗ |
| Route | Intravenous | “intravenous drip” NCT04178850 ↗ |